A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors

NCT02650713 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

228

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: Atezolizumab
DRUG: RO6958688

Sponsor

Hoffmann-La Roche